The most recent update discusses the prevalence, categorization, etiology, and treatment options for allergic eye illness. The prevalence of allergic eye illness is unknown, however it is thought to impact nearly all individuals with allergic rhinitis. In the United States, increased incidence of oculonasal symptoms have been recorded, resulting in considerable economic costs. Seasonal and perennial conjunctivitis, vernal and atopic keratoconjunctivitis, and large papillary conjunctivitis are all part of the allergic conjunctivitis spectrum. Patients with allergic conjunctivitis have immunoglobulin E-mediated pathophysiology, and first-line management strategies include allergen avoidance, traditional pharmacotherapy with oral antihistamines, topical dual-acting antihistamine/mast cell stabilizer agents, and treatment of tear film dysfunction. Immunotherapy is a useful therapeutic strategy, and refractory patients may require ophthalmology comanagement for topical ester-based corticosteroid therapy and topical immunomodulators.
Ocular allergy, which involves particular changeable and curable environmental sensitizations, is prevalent and often goes unnoticed. It can have various degrees of negative impact on one’s quality of life. Some instances are difficult to manage and may necessitate multidisciplinary care coordination between allergy and ophthalmology doctors. Understanding categorization, triggers, and treatment choices is critical in developing patient-tailored management programs.
Reference: https://journals.lww.com/co-allergy/Abstract/2016/10000/An_update_on_ocular_allergy.15.aspx
